AR061230A1 - EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA - Google Patents

EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA

Info

Publication number
AR061230A1
AR061230A1 ARP070102413A ARP070102413A AR061230A1 AR 061230 A1 AR061230 A1 AR 061230A1 AR P070102413 A ARP070102413 A AR P070102413A AR P070102413 A ARP070102413 A AR P070102413A AR 061230 A1 AR061230 A1 AR 061230A1
Authority
AR
Argentina
Prior art keywords
egf
tgf
survival
cancer
alfa
Prior art date
Application number
ARP070102413A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of AR061230A1 publication Critical patent/AR061230A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prolongacion de la supervivencia de un paciente con cáncer, donde el paciente produce un nivel elevado de EGF o TGF-alfa, tratando al paciente con un inhibidor de dimerizacion de HER, como pertuzumab.Prolongation of the survival of a cancer patient, where the patient produces an elevated level of EGF or TGF-alpha, treating the patient with an HER dimerization inhibitor, such as pertuzumab.

ARP070102413A 2006-06-05 2007-06-05 EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA AR061230A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81123406P 2006-06-05 2006-06-05

Publications (1)

Publication Number Publication Date
AR061230A1 true AR061230A1 (en) 2008-08-13

Family

ID=38691718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102413A AR061230A1 (en) 2006-06-05 2007-06-05 EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA

Country Status (13)

Country Link
US (1) US20080038271A1 (en)
EP (1) EP2035039A2 (en)
JP (1) JP2009539836A (en)
KR (1) KR20090019890A (en)
CN (1) CN101495142A (en)
AR (1) AR061230A1 (en)
AU (1) AU2007259171A1 (en)
BR (1) BRPI0712077A2 (en)
CA (1) CA2654584A1 (en)
CL (1) CL2007001602A1 (en)
MX (1) MX2008015581A (en)
TW (1) TW200815472A (en)
WO (1) WO2007145862A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PL217410B1 (en) 2000-05-19 2014-07-31 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
KR20150043558A (en) * 2004-07-22 2015-04-22 제넨테크, 인크. Her2 antibody composition
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CN102580084B (en) 2005-01-21 2016-11-23 健泰科生物技术公司 The fixed dosage of HER antibody is administered
SI1850874T1 (en) 2005-02-23 2014-01-31 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
IL282783B2 (en) * 2006-05-18 2023-09-01 Caris Mpi Inc System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
CL2007002881A1 (en) * 2006-10-20 2008-05-09 Amgen Inc STABLE FORMULATION THAT INCLUDES A TAMPON WITH A PH OF APPROXIMATELY 4 AND LESS THAN 6, A DIVALENT CATION OF 5-150 MM, A EXCIPIENT THAT INCLUDES A SUGAR OR A POLYOL, AND AN ANTI-RECEIVING ANTIBODY OF THE EPIDERMAL GROWTH FACTOR; AND METHOD
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2362783A2 (en) 2008-10-31 2011-09-07 Biogen Idec MA Inc. Light targeting molecules and uses thereof
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular profiling of tumors
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2016105962A (en) * 2009-12-04 2018-11-23 Дженентек, Инк. MULTI-SPECIFIC ANTIBODIES, ANTIBODIES ANALOGUES, COMPOSITIONS AND METHODS
ES2594893T3 (en) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anti HER2 antibodies and their uses
CA2783846C (en) * 2009-12-21 2021-01-19 Genentech, Inc. Antibody formulation
CN103003424B (en) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation
CN103270418A (en) * 2010-07-19 2013-08-28 霍夫曼-拉罗奇有限公司 Method to identify a patient with an increased likelihood of responding to an anti-ancer therapy
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
SG10201606756PA (en) 2011-10-14 2016-10-28 Genentech Inc Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
CN105121471A (en) 2013-04-16 2015-12-02 豪夫迈·罗氏有限公司 Pertuzumab variants and evaluation thereof
ES2813875T3 (en) 2014-01-01 2021-03-25 Medivation Tech Llc Compounds and procedures for use
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
JP6822980B2 (en) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド How to treat HER2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6914336B2 (en) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド Treatment of advanced HER2-expressing cancer
AU2018210312B2 (en) 2017-01-17 2020-03-19 F. Hoffmann-La Roche Ag Subcutaneous HER2 antibody formulations
EP3589661B1 (en) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10084743T1 (en) * 1999-06-25 2002-08-14 Genentech Inc Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
GT200500155A (en) * 2004-06-16 2006-05-15 PLATINUM-RESISTANT CANCER THERAPY
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor

Also Published As

Publication number Publication date
AU2007259171A1 (en) 2007-12-21
WO2007145862A2 (en) 2007-12-21
CL2007001602A1 (en) 2008-03-14
KR20090019890A (en) 2009-02-25
TW200815472A (en) 2008-04-01
WO2007145862B1 (en) 2008-05-02
WO2007145862A3 (en) 2008-02-28
MX2008015581A (en) 2008-12-17
CA2654584A1 (en) 2007-12-21
BRPI0712077A2 (en) 2012-01-17
JP2009539836A (en) 2009-11-19
CN101495142A (en) 2009-07-29
US20080038271A1 (en) 2008-02-14
EP2035039A2 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
AR061230A1 (en) EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA
CR9312A (en) LENGTH TIME UP TO THE PROGRESSION OF THE DISEASE OR SURVIVAL OF CANCER PATIENTS
DOP2013000212A (en) CRYSTAL FORMS OF DIMETOXI-DOCETAXEL AND ITS PREPARATION PROCEDURES
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
CY1118523T1 (en) Peptide compounds for the treatment of refractory STATUS EPILEPTICUS
MY163852A (en) Amidophenoxyindazoles useful as inhibitors of c-met.
CL2009000545A1 (en) Use of a c-met antagonist and a her antagonist for the treatment of cancer.
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
DOP2011000386A (en) ANTAGONISTS OF THE HEDGEHOG TRAJECTORY OF DISTTITUTED FTALAZINA
ECSP088536A (en) DERIVATIVES OF PIRIDO-, PIRAZO- AND PIRIMIDO-PIRIMIDINA AS MTOR INHIBITORS
SV2007002146A (en) DIFENYLIMIDAZOPIRIMIDINE AND IMIDAZOL AMINAS AS BETA-SECRETASA INHIBITORS REF. AM101727
NI200900184A (en) USE OF PI3K-ALPHA QUINAXOLINE INHIBITING COMPOUNDS FOR THE TREATMENT OF CANCER.
ECSP099445A (en) QUINAZOLINS FOR THE INHIBITION OF PDK1
MX2009009761A (en) Compositions and kits for treating influenza.
UY32551A (en) PEPTIDOMIMETIC COMPOUNDS OF SULFAMIDE AND ANTIVIRAL USES OF THE SAME
EA201170288A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
UY32554A (en) PEPTIDOMIMETIC COMPOUNDS OF SULFONAMIDE AND ANTIVIRAL USES OF THE SAME
CL2007002382A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of skin cancer.
BRPI0908635A8 (en) compound, pharmaceutical composition and cancer treatment method
CR20110202A (en) ANTAGONISTS OF THE VIA HEDGEHOG OF FTALAZINA DISUSTITUIDA
CL2011001943A1 (en) Antibiotic therapy to treat or prevent post-infectious irritable bowel syndrome.
CY1114217T1 (en) TREATMENT OF MELANOMA
MX2010008994A (en) Combination comprising paclitaxel for treating ovarian cancer.
MX2009009693A (en) Methods of activating irs-1 and akt.
EA200971067A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS

Legal Events

Date Code Title Description
FB Suspension of granting procedure